SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

NVIDIA Corp. engages in the design and manufacture of computer graphics processors, chipsets, and related multimedia software. It operates through the following segments: Graphics Processing Unit (GPU) and Compute & Networking. The Graphics segment includes GeForce GPUs for gaming and PCs, the GeForce NOW game streaming service and related infrastructure, Quadro and NVIDIA RTX GPUs for enterprise workstation graphics, virtual GPU, or vGPU, software for cloud-based visual and virtual computing, automotive platforms for infotainment systems, and Omniverse Enterprise software for building and operating metaverse and 3D internet applications. The Compute & Networking segment consists of Data Center accelerated computing platforms and end-to-end networking platforms including Quantum for InfiniBand and Spectrum for Ethernet, NVIDIA DRIVE automated-driving platform and automotive development agreements, Jetson robotics and other embedded platforms, NVIDIA AI Enterprise and other software, and DGX Cloud software and services. The company was founded by Jen Hsun Huang, Chris A. Malachowsky, and Curtis R. Priem in April 1993 and is headquartered in Santa Clara, CA.

NVIDIA Corp

Nvidia shares are under pressure as traders react to the boards investigation into Jensen Huangs admitted affair with a businesswoman reported to have suspected ties to Chinese intelligence, raising concerns about governance, possible information leaks, and Huangs future as CEO. The community is divided between seeing the probe and leadership uncertainty as a serious overhang and treating the controversy as unrelated to Nvidias AI-chip business and a buying opportunity.

Hims & Hers Health, Inc. operates a telehealth consultation platform. It connects consumers to healthcare professionals, enabling them to access medical care for mental health, sexual health, dermatology and primary care. The company was founded in 2017 and is headquartered in San Francisco, CA.

Hims & Hers Health Inc - Ordinary Shares - Class A

Hims & Hers Health Inc

Hims & Hers is under heavy selling pressure ahead of its Q3 earnings report, with traders speculating about a possible leak while others see the decline as pre-report positioning; a leak is unconfirmed. Bulls point to growth and potential upbeat guidance, while bears worry that the Eli Lilly obesity-drug deal could pressure margins and profitability.

TG Therapeutics, Inc. engages in the acquisition, development, and commercialization of novel treatments for B-cell malignancies and autoimmune diseases. Its product pipeline includes TG-1501, TG-1701, Ublituximab, and Umbralisib. The company was founded by Michael Sean Weiss and Laurence H. Shaw on May 18, 1993 and is headquartered in Morrisville, NC.

TG Therapeutics Inc

TG Therapeutics quarterly revenue beat and higher full-year outlook, driven by BRIUMVI growth, are the main focus; shares saw a sharp post-results dip and recovery, prompting debate over a sell the news reaction versus short-driven volatility. Traders are also watching for Phase 3 results on subcutaneous BRIUMVI as a next potential catalyst.

iShares Trust - iShares Russell 2000 Index Fund

iShares Russell 2000 ETF

IWMs sharp rally is drawing attention as small caps outperform, with traders describing a possible low-volume short squeeze and rotation into the Russell 2000. Bulls are chasing calls and citing hopes for easing inflation, while skeptics question the moves strength given reported weak flows and limited volume.

Capricor Therapeutics, Inc. is a clinical-stage biotechnology company, which focuses on the development of transformative cell and exosome-based therapeutics for treating Duchenne muscular dystrophy (“DMD”), a rare form of muscular dystrophy which results in muscle degeneration and premature death, and other diseases with unmet medical needs. Its product candidate consists of CAP-1002, Engineered Exosomes, CAP-2003, and Exosome-Based Vaccine. The company was founded on June 17, 1996 and is headquartered in San Diego, CA.

Capricor Therapeutics Inc

Capricors pending FDA decision on deramiocel for Duchenne muscular dystrophy, focused on the amended upper-limb-function evidence from HOPE-3, is driving attention ahead of the Nov. 22 PDUFA date. Bulls cite the trial data and a letter urging approval from 28 investigators, while skeptics point to FDA scrutiny and the earlier negative advisory-panel vote on the cardiac indication; short-squeeze speculation adds to the debate.

Advanced Micro Devices, Inc. engages in the semiconductor business. Its products include processors, accelerators, graphics, adaptive SoCs, FPGAs, and SOMs, and software, tools, and apps. The firm offers artificial intelligence, industries, workloads, and gaming solutions. The company was founded by W. J. Sanders III on May 1, 1969 and is headquartered in Santa Clara, CA.

Advanced Micro Devices Inc.

Advanced Micro Devices Inc

AMDs rally is drawing attention after Oppenheimer upgraded the stock, while Google Clouds use of EPYC processors in its AI infrastructure added a company-specific catalyst. Traders also point to money rotating from Nvidia amid a CEO-related investigation, though some see the move as sentiment-driven and question AMDs valuation.

Candel Therapeutics, Inc. is a clinical stage biotechnology company, which engages in the development and commercialization of viral immunotherapies. Its pipeline includes CAN-2409 and CAN-3110. The company was founded by Estuardo Aguilar-Cordova in 2002 and is headquartered in Needham, MA.

Candel Therapeutics Inc

Candels SITC findings on immune activation and viral clearance, alongside its positive Phase 3 prostate-cancer results, are drawing attention as the company prepares a BLA for CAN-2409. Bulls see the data as supportive of the regulatory package, while skeptics question filing and manufacturing execution and warn of a possible sell-the-news reaction.

Axon Enterprise, Inc. engages in the development, manufacture, and sale of conducted electrical weapons for personal defense. It operates through the TASER segment and Software and Sensors segment. The TASER segment sells conducted electrical weapons, accessories, and other related products and services. The Software and Sensors segment includes devices, wearables, applications, cloud, and mobile products. The company was founded by Patrick W. Smith and Thomas P. Smith on September 7, 1993 and is headquartered in Scottsdale, AZ.

Axon Enterprise Inc

A quarterly earnings shortfall and reduced full-year revenue guidance, tied largely to federal Dedrone drone deployments being delayed, have driven a sharp selloff. Traders debate whether the decline overreacts to a timing issue or reflects high valuation and weaker near-term growth, with some buying the dip and others expecting further downside.

The Trade Desk, Inc. engages in the provision of a self-service and cloud-based ad-buying platform. The firm operates through the following geographical segments: United States and International. It offers omnichannel advertising, audience targeting, solutions for identity, application programming interface (API), custom, and programmatic, measurement and optimization. The company was founded by Jeffrey Terry Green and David Pickles in November 2009 and is headquartered in Ventura, CA.

Trade Desk Inc - Ordinary Shares - Class A

Trade Desk Inc

Trade Desk shares are rallying sharply ahead of its Q3 earnings report, with traders speculating about short covering and an earnings leak, though neither explanation is confirmed. The move has fueled hopes for a turnaround, while many investors worry that weak results or guidance could erase the gains.

Churchill Capital Corp. XI is a blank check company. It was formed for the purpose of effecting a merger, amalgamation, share exchange, asset acquisition, share purchase, reorganization or similar business combination with one or more businesses. The company was founded by Michael Stuart Klein on June 4, 2025 and is headquartered in New York, NY.

Agility Robotics Inc.

Agility Robotics Inc. - Ordinary Shares - Class A

Post-merger selling in Agility Robotics is drawing attention, with traders pointing to typical de-SPAC volatility and questioning the companys steep losses, limited revenue, and path to commercial scale. Some remain bullish on humanoid robotics and the companys reported orders, but the discussion is dominated by skepticism about valuation and near-term execution.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

Nvidia To Rally Around 146%? Here Are 10 Top Analyst Forecasts For Thursday

Wall Street analysts changed outlook on top names: Evercore raised Salesforce target, Needham raised Nutanix target, Ascendiant raised PAVmed target, Cantor raised Okta target, Piper raised Veeva target, Cantor boosted Solid Biosciences target, BTIG raised Crowdstrike target, Cantor cut Dycom...

Capricor Says FDA Used 'Obsolete' Analysis In Deramiocel Review – CAPR Stock Plummets After Agency Released Briefing Document

Equity

The FDA released briefing documents, raising concerns over whether Capricor’s lead therapy, Deramiocel, has demonstrated sufficient effectiveness in treating cardiomyopathy in patients with Duchenne muscular dystrophy.


Where Will Solid Biosciences Inc (SLDB) Stock Be in the Next 12 Months?

Where Will Solid Biosciences Inc (SLDB) Stock Be in the Next 12 Months...

Solid Biosciences (NASDAQ:SLDB) Rating Increased to Strong-Buy at Truist Financial

Truist Financial raised shares of Solid Biosciences to a "strong-buy" rating in a research note on Monday...

Solid Biosciences (NASDAQ:SLDB) Downgraded to Sell Rating by Wall Street Zen

Wall Street Zen lowered shares of Solid Biosciences from a "hold" rating to a "sell" rating in a report on Sunday...

Solid Biosciences Inc. (NASDAQ:SLDB) Receives Average Recommendation of "Moderate Buy" from Brokerages

Shares of Solid Biosciences Inc. (NASDAQ:SLDB - Get Free Report) have received a consensus recommendation of "Moderate Buy" from the thirteen research firms that are currently covering the stock...

Solid Biosciences (NASDAQ:SLDB) Sets New 12-Month High  - Here's What Happened

Solid Biosciences (NASDAQ:SLDB) Hits New 12-Month High - What's Next...

Solid Biosciences (NASDAQ:SLDB) Stock Price Down 3.9% - Here's Why

Solid Biosciences (NASDAQ:SLDB) Stock Price Down 3.9% - What's Next...

Solid Biosciences (NASDAQ:SLDB) Raised to "Hold" at Wall Street Zen

Wall Street Zen raised Solid Biosciences from a "sell" rating to a "hold" rating in a report on Saturday...

Solid Biosciences (NASDAQ:SLDB) Trading 6.4% Higher - Here's What Happened

Solid Biosciences (NASDAQ:SLDB) Shares Up 6.4% - Here's What Happened...

Solid Biosciences, Inc. is a life science company, which engages in the development of treatments for patients with Duchenne muscular dystrophy. It also focuses on developing treatments for neuromuscular and cardiac diseases. The company was founded by Ilan Ganot, Andrey J. Zarur, Matthew Bennett Arnold, Annie Ganot, and Gilad David Hayeem in March 2013 and is headquartered in Charlestown, MA.

Solid Biosciences Inc

Bearish Sentiment

<ul class="summary-bullets"><li>FDA reviewers said the study failed to meet its pre-specified primary and secondary efficacy endpoints, finding no statistically significant difference between Deramiocel and placebo after 12 months.</li><li>The documents show that reviewers raised concerns over changes made to the statistical analysis plan for Capricor’s Phase 3 Hope-3 trial.</li><li>Capricor said the FDA’s review was based on an unsigned, incomplete, and obsolete internal draft.</li></ul>Shares of Capricor Therapeutics (CAPR) tanked more than 67% on Monday after U.S. Food and Drug Administration (FDA) reviewers expressed concerns in briefing documents over whether its lead therapy Deramiocel has shown sufficient effectiveness to treat cardiomyopathy in patients with Duchenne muscular dystrophy (DMD).However, the company responded by stating that the FDA’s review was based on an unsigned, incomplete, and obsolete internal draft.&nbsp;“Our results are governed by the final analysis plan, SAP version 3.0, which was finalized prior to unblinding. It is critical to understand that the post-hoc analyses in the FDA’s briefing materials rely on SAP version 1.1, an unsigned, incomplete internal draft which became obsolete with the addition of cohort B and did not include content specifically requested by FDA,” said CEO Linda Marbán.&nbsp;&nbsp;<a href="https://stocktwits.com/symbol/CAPR">CAPR stock</a> also recorded its biggest ever single-day slide. It is currently at its lowest levels since December 2025.<h2 class="st-heading-2">Reviewers Say Deramiocel Study Fails to Meet Primary, Secondary Efficacy Endpoints</h2>The FDA on Monday&nbsp;<a class="st-link-external" target="_blank" rel="noopener noreferrer nofollow" href="https://www.fda.gov/advisory-committees/advisory-committee-calendar/cellular-tissue-and-gene-therapies-advisory-committee-july-29-2026-meeting-announcement-updated">released</a> briefing documents ahead of a July 29 meeting of its Cellular, Tissue, and Gene Therapies Advisory Committee. In the documents, FDA reviewers said the study failed to meet its pre-specified primary and secondary efficacy endpoints, finding no statistically significant difference between Deramiocel and placebo after 12 months.Duchenne muscular dystrophy is a rare inherited disorder that mainly affects boys, causing progressive muscle weakness, and there are no FDA-approved treatments specifically for the heart disease that often develops as the condition worsens.The advisory committee will review Capricor’s Biologics License Application (BLA) for the drug before the FDA makes its final decision by the Prescription Drug User Fee Act (PDUFA) target date of Aug. 22, 2026. A PDUFA date is the deadline by which the FDA decides whether to approve a drug for marketing in the United States.<h2 class="st-heading-2">Reviewers Question Changes To Trial Analysis</h2>The documents show that reviewers raised concerns over changes made to the statistical analysis plan (SAP) for Capricor’s Phase 3 Hope-3 trial. In December 2025, Capricor stated that its Phase 3 Hope-3 trial met its primary endpoint of improving upper-limb function and its key secondary endpoint of preserving heart function, with both showing statistically significant results.However, the reviewers said multiple changes were made after the randomized portion of the study, including revisions to the primary and secondary endpoints, analytical methods, and data imputation strategy. They also noted that the final SAP was not submitted for review before the company’s BLA and that the study’s pre-specified procedures for making such changes were not followed.&nbsp;The documents also highlighted a higher rate of hypersensitivity reactions in patients treated with Deramiocel, which it said may have increased the risk of functional unblinding during the trial.<h2 class="st-heading-2">What’s Next?</h2>The advisory committee has been recommended to discuss whether data from the Hope-3 and Hope-2 studies show that Deramiocel can slow the decline in heart function in patients with Duchenne muscular dystrophy.The panel will also consider whether the combined results provide enough evidence that the therapy improves upper-limb function and is an effective treatment for the disease.<h2 class="st-heading-2">Retail’s Take On CAPR</h2>Despite the slump, retail sentiment on Stocktwits turned ‘extremely bullish’ from ‘bullish’ a day earlier, amid a 320% jump in message volumes. CAPR was also among the top trending stocks on the platform at the time of writing.One user said there’s a “60% chance that they will have to redo the Adequate and controlled cardiac primary trial.”<stembedurl>https://stocktwits.com/PB09/message/660074196</stembedurl>However, another user was confident that Capricor will be able to answer whatever questions the committee will have with “proven data and results.”<stembedurl>https://stocktwits.com/Stormfury66/message/660074439</stembedurl>The stock has shed more than 77% so far this year.Also read:&nbsp;<a href="https://stocktwits.com/news-articles/markets/equity/fbrx-stock-surges-why-argenx-buying-forte-biosciences/cZZxWT5R7Cr">FBRX Stock On Track For Highest Levels In Over 4.5 Years As ArgenX Scoops Up Autoimmune Drug Maker</a>For updates and corrections, email newsroom[at]stocktwits[dot]com.

In this photo illustration, the lCapricor Therapeutics logo is seen displayed on the screen of a tablet. (Photo Illustration by Sheldon Cooper/SOPA Images/LightRocket via Getty Images)

Shares of Capricor Therapeutics (CAPR) tanked more than 67% on Monday after U.S. Food and Drug Administration (FDA) reviewers expressed concerns in briefing documents over whether its lead therapy Deramiocel has shown sufficient effectiveness to treat car

Sarepta Therapeutics Inc

Buying the dip

Selling or trimming

Holding

Waiting for the investigation results to decide

Nvidia ($NVDA) is down about 4% after its board opened an investigation into CEO Jensen Huang. What are you doing with the stock?

Stocktwits

) is down about 4% after its board opened an investigation into CEO Jensen Huang. What are you doing with the stock?

Current Price	$7.15
Prev Close	$6.59
Open	$6.65
Dividend Yield	0.00%
50-Day Moving Average	$7.48
Beta	1.98
Avg. Volume	1.36M
PE Ratio	-3.70

52-Week High	$11.45
52-Week Low	$4.01
Market Capitalization	$735.51M
EPS (Annual)	-$1.99
Price to Book	2.15
Revenue Per Employee	$0.00

Feed

News

Sentiment

Earnings

Fundamentals

Info

SLDB Fundamentals